Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Short-term Investments (2016 - 2022)

Historic Short-term Investments for Catalyst Pharmaceuticals (CPRX) over the last 12 years, with Q2 2022 value amounting to $9.9 million.

  • Catalyst Pharmaceuticals' Short-term Investments fell 5057.06% to $9.9 million in Q2 2022 from the same period last year, while for Jun 2022 it was $9.9 million, marking a year-over-year decrease of 5057.06%. This contributed to the annual value of $19.8 million for FY2021, which is 9740.07% up from last year.
  • Catalyst Pharmaceuticals' Short-term Investments amounted to $9.9 million in Q2 2022, which was down 5057.06% from $19.4 million recorded in Q1 2022.
  • Catalyst Pharmaceuticals' Short-term Investments' 5-year high stood at $58.5 million during Q2 2018, with a 5-year trough of $5.0 million in Q4 2019.
  • For the 5-year period, Catalyst Pharmaceuticals' Short-term Investments averaged around $26.8 million, with its median value being $20.0 million (2021).
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Short-term Investments soared by 12043.73% in 2018 and then tumbled by 8643.89% in 2019.
  • Catalyst Pharmaceuticals' Short-term Investments (Quarter) stood at $36.9 million in 2018, then crashed by 86.44% to $5.0 million in 2019, then surged by 100.54% to $10.0 million in 2020, then skyrocketed by 97.4% to $19.8 million in 2021, then tumbled by 50.17% to $9.9 million in 2022.
  • Its Short-term Investments stands at $9.9 million for Q2 2022, versus $19.4 million for Q1 2022 and $19.8 million for Q4 2021.